-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|April 24, 2013

Rennee Rayburg, RPh, Discusses the Top Down Approach in Specialty Drug Management

Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.

Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight, states that if providers narrowly focus on the traditional top down approach in specialty drug management they may miss out on opportunities for additional cost savings.

When providers only focus on their top drivers, they fail to recognize the impact specialty drug patients can have on pushing higher costs. Rayburg says, “When you look at a rare disease and a drug that might cost you a couple hundred thousand dollars a year, it’s going to make a difference if you have one or two of those in your population of people.”


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.